Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 12 (December)

1. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer.
   Br J Surg, 92(12): 1494-7. [Abstract] [Full-text]
2. Inhibition of phosphatidylinositol 3-kinase/protein kinase B signaling is not sufficient to account for indole-3-carbinol-induced apoptosis in some breast and prostate tumor cells.
   Clin Cancer Res, 11(23): 8521-7. [Abstract] [Full-text]
3. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
   Clin Cancer Res, 11(23): 8425-30. [Abstract] [Full-text]
4. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
   Clin Cancer Res, 11(23): 8398-402. [Abstract] [Full-text]
5. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
   Clin Cancer Res, 11(23): 8348-57. [Abstract] [Full-text]
6. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.
   Clin Cancer Res, 11(23): 8312-20. [Abstract] [Full-text]
7. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
   Lancet, 366(9501): 1935-44. [Abstract] [Full-text]
8. Intrameningioma metastasis as first clinical manifestation of occult primary breast carcinoma.
   Neurosurg Rev, 29(1): 49-54. [Abstract] [Full-text]
9. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
   Int J Cancer, 118(3): 755-64. [Abstract] [Full-text]
10. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
    Int J Cancer, 118(3): 658-67. [Abstract] [Full-text]
11. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.
    Int J Cancer, 118(3): 696-703. [Abstract] [Full-text]
12. Preschool diet and adult risk of breast cancer.
    Int J Cancer, 118(3): 749-54. [Abstract] [Full-text]
13. Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany--final results of a survey among german breast cancer specialists.
    Onkologie, 28(12): 639-44. [Abstract] [Full-text]
14. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
    J Natl Cancer Inst, 97(23): 1746-59. [Abstract] [Full-text]
15. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    J Natl Cancer Inst, 97(23): 1724-33. [Abstract] [Full-text]
16. Science and society: the Long Island Breast Cancer Study Project.
    Nat Rev Cancer, 5(12): 986-94. [Abstract] [Full-text]
17. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes.
    Nat Rev Cancer, 5(12): 977-85. [Abstract] [Full-text]
18. Expression of VDR and CYP24A1 mRNA in human tumors.
    Cancer Chemother Pharmacol, 57(2): 234-40. [Abstract] [Full-text]
19. Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.
    Cancer Chemother Pharmacol, 57(2): 135-44. [Abstract] [Full-text]
20. Thiolo-, thiono- and dithiocarbonate and thiocarbamate derivatives of demethylpenclomedine as novel anticancer agents.
    Cancer Chemother Pharmacol, 57(2): 180-4. [Abstract] [Full-text]
21. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
    Cancer Chemother Pharmacol, 57(2): 145-54. [Abstract] [Full-text]
22. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage.
    Nano Lett, 5(12): 2573-7. [Abstract] [Full-text]
23. Diagnostic mammography performance and race: outcomes in Black and White women.
    Cancer, 104(12): 2671-81. [Abstract] [Full-text]
24. Angiosarcoma of the breast.
    Cancer, 104(12): 2682-8. [Abstract] [Full-text]
25. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
    Oncogene, 24(56): 8343-8. [Abstract] [Full-text]
26. Resensitization of breast cancer cells to anoikis by tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion.
    Oncogene, 24(56): 8291-303. [Abstract] [Full-text]
27. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
    Clin Cancer Res, 11(24): 8837-44. [Abstract] [Full-text]
28. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
    Clin Cancer Res, 11(24): 8722-7. [Abstract] [Full-text]
29. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Clin Cancer Res, 11(24): 8715-21. [Abstract] [Full-text]
30. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
    Clin Cancer Res, 11(24): 8623-31. [Abstract] [Full-text]
31. The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors.
    Clin Cancer Res, 11(24): 8577-84. [Abstract] [Full-text]
32. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
    Lancet, 366(9503): 2087-106. [Abstract] [Full-text]
33. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).
    Semin Oncol, 32(6): S22-6. [Abstract] [Full-text]
34. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
    Semin Oncol, 32(6): S16-21. [Abstract] [Full-text]
35. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis.
    Semin Oncol, 32(6): S9-15. [Abstract] [Full-text]
36. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).
    Semin Oncol, 32(6): S3-8. [Abstract] [Full-text]
37. In a randomized controlled trial, patients preferred electronic data collection of breast cancer risk-factor information in a mammography setting.
    J Clin Epidemiol, 59(1): 77-81. [Abstract] [Full-text]
38. Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.
    J Clin Epidemiol, 59(1): 53-60. [Abstract] [Full-text]
39. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma.
    Hum Pathol, 37(1): 9-15. [Abstract] [Full-text]
40. Reconstructive breast implantation after mastectomy for breast cancer: clinical outcomes in a nationwide prospective cohort study.
    Arch Surg, 140(12): 1152-9; discussion 1160-1. [Abstract] [Full-text]
41. Modulation of RIZ gene expression is associated to estradiol control of MCF-7 breast cancer cell proliferation.
    Exp Cell Res, 312(3): 340-9. [Abstract] [Full-text]
42. S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth.
    Exp Cell Res, 312(3): 278-88. [Abstract] [Full-text]
43. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study.
    Radiology, 238(1): 42-53. [Abstract] [Full-text]
44. Characterization of integrin and anchorage dependence in mammary epithelial cells following c-erbB2-induced epithelial-mesenchymal transition.
    Tumour Biol, 27(1): 50-8. [Abstract] [Full-text]
45. Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell.
    Tumour Biol, 27(1): 17-26. [Abstract] [Full-text]
46. MR imaging-guided 9-gauge vacuum-assisted core-needle breast biopsy: initial experience.
    Radiology, 238(1): 54-61. [Abstract] [Full-text]
47. Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR.
    Biochem Biophys Res Commun, 340(1): 268-76. [Abstract] [Full-text]
48. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.
    Biochem Biophys Res Commun, 340(1): 175-82. [Abstract] [Full-text]
49. Flow cytometry: a new approach for the molecular profiling of breast cancer.
    Exp Mol Pathol, 80(1): 46-53. [Abstract] [Full-text]
50. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort.
    Int J Cancer, 118(5): 1285-91. [Abstract] [Full-text]
51. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer.
    Int J Cancer, 118(5): 1292-301. [Abstract] [Full-text]
52. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer.
    Int J Cancer, 118(5): 1279-84. [Abstract] [Full-text]
53. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Int J Cancer, 118(5): 1126-34. [Abstract] [Full-text]
54. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma.
    Int J Cancer, 118(5): 1241-7. [Abstract] [Full-text]
55. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors.
    Int J Cancer, 118(5): 1205-14. [Abstract] [Full-text]
56. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
    Int J Cancer, 118(5): 1215-26. [Abstract] [Full-text]
57. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).
    J Virol, 80(2): 845-53. [Abstract] [Full-text]
58. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    N Engl J Med, 353(26): 2747-57. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.